Erratum: Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery (J. Med. Chem. (2021) 64:10 (6523−6548) DOI: 10.1021/acs.jmedchem.1c00028)

Page 6526. In the last paragraph on this page we mentioned that "Novel NMDA receptor antagonists like 19, NYX-2925 (20), and RL-208 (21) were recently designed and synthesized (Figure 2); however, these compounds were not tested for activity in rodent pain models. 1-3"We would like to make the correction that, NYX-2925 is not an NMDA receptor antagonist but a glutamate coligand that positively modulates the NMDA receptor and binds all 4 NMDAR2A-D subtypes to facilitate channel opening even in the absence of glycine. NYX- 2925 is currently in Phase II clinical development for the treatment of painful, diabetic peripheral neuropathy and fibromyalgia following xtensive characterization in rodent models and may represent a unique mechanism for the treatment of chronic, supraspinal centralized pain conditions. 4-6.